| Annual · values | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.66 M USD | -14.48 M USD | -31.51 M USD | -45.06 M USD | -35.17 M USD | -19.60 M USD |
| Depreciation & Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — |
| Capital Expenditures | — | — | — | — | — | — |
| Cash Flow from Investing | — | — | — | — | — | — |
| Cash Flow from Financing | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — |
| Free Cash Flow | -13.33 M USD | -16.02 M USD | -32.32 M USD | -45.23 M USD | -35.76 M USD | -18.34 M USD |
Viveve Medical Inc. specializes in the design, development, manufacturing, and marketing of medical devices primarily focused on women's health. Its flagship product, the Viveve System, employs Cryogen-cooled Monopolar Radiofrequency technology for non-invasive treatments addressing vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. This innovative medical technology plays a significant role in enhancing women's well-being by offering low-risk, high-reward procedures. Viveve Medical Inc. operates across a global network, including the Americas, Europe, and Asia-Pacific regions, making it a notable player in the healthcare sector, particularly within the medical devices industry.